Cargando…
Marked Hypoleptinemia Precedes Overt Fat Loss in Immune Checkpoint Inhibitor-induced Acquired Generalized Lipodystrophy
Immune checkpoint inhibitors (ICIs) targeting cancer cells that evade immune T-cell regulation have revolutionized the treatment of metastatic carcinomas. Unfortunately, secondary endocrinopathies associated with ICI, including adrenal insufficiency, primary hypothyroidism, autoimmune diabetes, and...
Autores principales: | Dhanasekaran, Maheswaran, Sandooja, Rashi, Higgins, Alexandra S, Simha, Vinaya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10580409/ https://www.ncbi.nlm.nih.gov/pubmed/37908472 http://dx.doi.org/10.1210/jcemcr/luad025 |
Ejemplares similares
-
Increased Growth Differentiation Factor 15 in Patients with Hypoleptinemia-Associated Lipodystrophy
por: Kralisch, Susan, et al.
Publicado: (2020) -
Metreleptin Treatment in Three Patients with Generalized Lipodystrophy
por: Musso, Carla, et al.
Publicado: (2017) -
UCP1-independent glucose-lowering effect of leptin in type 1 diabetes: only in conditions of hypoleptinemia
por: Zouhar, Petr, et al.
Publicado: (2020) -
Untangling the Heterogeneity of Acquired Generalized Lipodystrophy
por: Cavdar, Umit, et al.
Publicado: (2021) -
Acquired Partial Lipodystrophy (Barraquer-Simons Syndrome): Early Cosmetic Intervention with Autologous Fat
por: Rho, Nark-Kyoung, et al.
Publicado: (2018)